相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial
R. B. Warren et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review
Kevin Yang et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)
Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
Yinuo Pang et al.
CLINICAL PHARMACOKINETICS (2020)
Psoriasis and Cardiovascular Risk: A Comprehensive Review
Walter Masson et al.
ADVANCES IN THERAPY (2020)
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis A Phase 3 Randomized Clinical Trial
Andrew Blauvelt et al.
JAMA DERMATOLOGY (2020)
Treatment of Psoriasis With Biologic Therapy Is Associated With Improvement of Coronary Artery Plaque Lipid-Rich Necrotic Core Results From a Prospective, Observational Study
Harry Choi et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2020)
Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab
Florence Poizeau et al.
JAMA DERMATOLOGY (2020)
Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2019)
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study
Kenneth B. Gordon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
Kristian Reich et al.
LANCET (2019)
In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis
Sarah A. R. Siegel et al.
CURRENT RHEUMATOLOGY REPORTS (2019)
IL-23 supports host defense against systemic Candida albicans infection by ensuring myeloid cell survival
Selim Nur et al.
PLOS PATHOGENS (2019)
Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer
Juming Yan et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom
Junko Takeshita et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Herpes Zoster Rates in a Large Cohort of Patients With Systemically Treated Psoriasis
Katherine A. Levandoski et al.
JAMA DERMATOLOGY (2018)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon et al.
LANCET (2018)
Co-morbidity in psoriasis: mechanisms and implications for treatment
Ann Sophie Lonnberg et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)
Hidehisa Saeki et al.
JOURNAL OF DERMATOLOGY (2017)
Psoriasis and comorbid diseases Epidemiology
Junko Takeshita et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab
Tiago Torres
DRUGS (2017)
Psoriasis and cardiovascular events: updating the evidence
Line Raaby et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2017)
The Risk of Cancer in Patients With Psoriasis A Population-Based Cohort Study in the Health Improvement Network
Zelma C. Chiesa Fuxench et al.
JAMA DERMATOLOGY (2016)
Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States
A. B. Kimball et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies
Andrew Blauvelt et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody
Sanjaya Singh et al.
MABS (2015)
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study
John W. Baddley et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the USA: 2005-09
A. B. Kimball et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Observational Studies
Ehrin J. Armstrong et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis
Kenneth B. Gordon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events
Nehal N. Mehta et al.
AMERICAN JOURNAL OF MEDICINE (2011)
Increased risk of infectious disease requiring hospitalization among patients with psoriasis: A population-based cohort
Marlies Wakkee et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials
Erica D. Dommasch et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009
C. H. Smith et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance
Teresa Zelante et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
分享论文
